ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc (FDMT)

4,53
0,05
(1,12%)
Fermé 02 Mars 10:00PM
4,63
0,10
(2,21%)
Après les heures de négociation: 1:45AM

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
4,63
Prix Achat
2,71
Prix Vente
15,00
Volume échangé
1 228 231
4,20 Fourchette du Jour 4,55
4,405 Plage de 52 semaines 36,25
Cap du marché
Clôture Veille
4,48
Ouverture
4,48
Dernière Transaction
100
@
4.63
(formt)
Dernière heure de transaction
Volume financier
US$ 5 449 152
VWAP
4,4366
Volume moyen (3 m)
930 490
Actions en circulation
46 227 709
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-2,09
Bénéfice par action (BPA)
-2,18
Chiffre d'affairess
20,72M
Bénéfice net
-100,84M

À propos de 4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (... 4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Siège social
Wilmington, Delaware, USA
Fondé
-
4D Molecular Therapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker FDMT. Le dernier cours de clôture d'4D Molecular Therapeutics était de US$4,48. Au cours de la dernière année, les actions de 4D Molecular Therapeutics ont été négociées dans une fourchette de prix de US$ 4,405 à US$ 36,25.

4D Molecular Therapeutics compte actuellement 46 227 709 actions en circulation. La capitalisation boursière d'4D Molecular Therapeutics est de US$207,10 million. 4D Molecular Therapeutics a un ratio cours/bénéfice (ratio PE) de -2.09.

FDMT Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.11-2.320675105494.744.8654.445161764.60477472CS
4-0.99-17.6156583635.626.914.4059669785.32676437CS
12-2.23-32.50728862976.867.584.4059304905.62873258CS
26-10.87-70.129032258115.517.414.4058915398.12274004CS
52-25.02-84.384485666129.6536.254.40581174114.76444683CS
156-9.76-67.824878387814.3936.254.40557311616.75132491CS
260-35.37-88.4254055.114.40546567218.26172487CS

FDMT - Frequently Asked Questions (FAQ)

What is the current 4D Molecular Therapeutics share price?
The current share price of 4D Molecular Therapeutics is US$ 4,63
How many 4D Molecular Therapeutics shares are in issue?
4D Molecular Therapeutics has 46 227 709 shares in issue
What is the market cap of 4D Molecular Therapeutics?
The market capitalisation of 4D Molecular Therapeutics is USD 207,1M
What is the 1 year trading range for 4D Molecular Therapeutics share price?
4D Molecular Therapeutics has traded in the range of US$ 4,405 to US$ 36,25 during the past year
What is the PE ratio of 4D Molecular Therapeutics?
The price to earnings ratio of 4D Molecular Therapeutics is -2,09
What is the cash to sales ratio of 4D Molecular Therapeutics?
The cash to sales ratio of 4D Molecular Therapeutics is 10,15
What is the reporting currency for 4D Molecular Therapeutics?
4D Molecular Therapeutics reports financial results in USD
What is the latest annual turnover for 4D Molecular Therapeutics?
The latest annual turnover of 4D Molecular Therapeutics is USD 20,72M
What is the latest annual profit for 4D Molecular Therapeutics?
The latest annual profit of 4D Molecular Therapeutics is USD -100,84M
What is the registered address of 4D Molecular Therapeutics?
The registered address for 4D Molecular Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the 4D Molecular Therapeutics website address?
The website address for 4D Molecular Therapeutics is www.4dmoleculartherapeutics.com
Which industry sector does 4D Molecular Therapeutics operate in?
4D Molecular Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
STAKSTAK Inc
US$ 3,97
(156,13%)
173,35k
ORGOOrganogenesis Holdings Inc
US$ 6,21
(102,28%)
58,69M
TRNRInteractive Strength Inc
US$ 2,57
(67,97%)
192,48M
PMAXPowell Max Ltd
US$ 0,511
(43,54%)
136,35M
ARBBARB IOT Group Ltd
US$ 0,6635
(38,23%)
58,86M
NVNINVNI Group Ltd
US$ 0,99
(-50,50%)
72,79M
SPGCSacks Parente Golf Inc
US$ 0,2085
(-48,65%)
58,21M
ADGMAdagio Medical Holdings Inc
US$ 0,8081
(-47,53%)
756,76k
PRAXPraxis Precision Medicines Inc
US$ 38,60
(-40,64%)
3,2M
SAGSAG Holdings Ltd
US$ 1,19
(-38,97%)
789,86k
NVDANVIDIA Corporation
US$ 124,92
(3,97%)
389,48M
TRNRInteractive Strength Inc
US$ 2,57
(67,97%)
193,57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 13,44
(7,78%)
154,46M
PMAXPowell Max Ltd
US$ 0,511
(43,54%)
137,18M
LCIDLucid Group Inc
US$ 2,22
(-0,45%)
136,17M
Aucune Discussion Trouvée
Ajouter une Discussion